Solution Delivery TRIZ Cases

PET/CT uptake screening guides Copper-64 dosing and patient selection, improving biodistribution control in cancer treatment.

Using mRNA and lipid nanoparticles, this case shows how cancer vaccines avoid DNA integration while producing earlier, stronger immune responses.

A core-shell polymer and cellulose shell resists stomach acid yet disintegrates at intestinal pH, avoiding thick enteric coatings.

Droplet evaporation under Peclet number control forms circular therapeutic particles with low internal voids, stable structure, and tunable surface enrichment.

A fluidic dilution approach creates radiopharmaceutical batches with matched activity at different application times from one calibrated bulk solution.

Ascorbate-based 177Lu-PSMA I&T synthesis limits radiolysis, delivering high purity and multi-day stability during storage at 30°C.

Sequential gentisic acid and ascorbic acid stabilization enables concentrated radionuclide solutions with 3-day shelf life and ready-to-use dosing.

Cyclodextrin co-stabilization helps radiopharmaceuticals resist radiolysis and maintain radiochemical purity at high radioactive concentrations.

Buffered pH 7.0-8.9 with ascorbic acid helps 225Ac radiopharmaceuticals resist radiolysis and stay above 91% purity for 168 hours.

Sequential gentisic acid and ascorbic acid stabilization enables concentrated radionuclide solutions that stay stable in storage and ship ready to use.

Sequential gentisic acid and ascorbic acid addition limits radiolytic degradation in concentrated radionuclide solutions for 72-hour ready-to-use storage.

A bulk-solution dilution approach keeps radiopharmaceutical activity and composition consistent across different application times in one fill process.

By lowering lipophilicity, this F-18 α-synuclein PET tracer crosses the blood-brain barrier and reduces non-specific binding in Parkinson's lesion imaging.